Shares of Veeva Systems (NYSE:VEEV), a company focused on providing cloud solutions to pharmaceutical companies, rose as much as 12% yesterday. Many were left wondering what accounted for such a big jump.
After a little digging, I believe I've found the most likely culprit: a survey released by Veeva itself outlining how outdated many pharmaceutical and life sciences companies are when it comes to clinical data collection. The document also notes the value proposition that Veeva can offer potential clients.
The slideshow below highlights the biggest takeaways from the report, and what they could mean for Veeva moving forward.
Brian Stoffel owns shares of Veeva Systems. The Motley Fool recommends Salesforce.com. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.